{
    "clinical_study": {
        "@rank": "94300", 
        "brief_summary": {
            "textblock": "To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine (\n      AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to\n      demonstrate that ddC monotherapy is safe, and tolerable in this patient population."
        }, 
        "brief_title": "Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Aerosolized Pentamidine or Trimethoprim/sulfamethoxazole prophylaxis against\n             Pneumocystis carinii pneumonia is recommended.\n\n          -  Dapsone is permitted but discouraged.\n\n          -  Drugs that could cause other serious toxicity when coadministered with study\n             medication is allowed for treatment of an acute intercurrent illness or opportunistic\n             infection at the investigator's discretion.\n\n          -  Any medication that has the potential to cause peripheral neuropathy should be\n             avoided; patients should consult their physicians for specific drugs.\n\n          -  Isoniazid is permitted if there is no evidence of peripheral neuropathy at entry and\n             the patient is taking pyridoxine = or > 50 mg/day.\n\n          -  Metronidazole is permitted only with a study drug interruption.\n\n          -  Patients on amphotericin, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole,\n             ganciclovir, intravenous pentamidine, intravenous acyclovir = or > 1000 mg/day orally\n             or other bone marrow or renal toxic drugs may not tolerate concomitant ddC. If these\n             drugs are given concomitantly with ddC, patients should have frequent (weekly)\n             laboratory assessments, as appropriate.\n\n          -  Drugs that are nephrotoxic or have the potential to cause peripheral neuropathy might\n             be expected to cause increased toxicity when co-administered with ddC.\n\n          -  The following experimental medications are allowed if, in the judgement of the\n             investigator, no serious additive toxicities are anticipated and the experimental\n             drug is necessary for optimal patient management:\n\n          -  Ampligen, azithromycin, BW 566C80, bovine colostrum, clarithromycin, diclazuril,\n             foscarnet, oral ganciclovir, GM-CSF, G-CSF, hypericin, IL-2, interferon-beta,\n             interferon-gamma, itraconazole, liposomal amphotericin, liposomal gentamicin,\n             nimodipine, PEG-IL2 (polyethylene glycosylated IL-2), roxithromycin, spiramycin,\n             trimetrexate.\n\n        Patients must have the following:\n\n          -  AIDS or Advanced ARC.\n\n          -  Patients eligible to enter this protocol must fall into one of the following three\n             categories:\n\n          -  AZT treatment failure or AZT intolerance or AZT ineligibility or Rollover Patients\n             Under 18 years of age must have the consent of a parent or guardian.\n\n        Exclusion Criteria\n\n        Patients with the following are excluded:\n\n          -  Any history of peripheral neuropathy due to any cause, even if peripheral neuropathy\n             was not the reason for discontinuation of other anti-HIV therapy.\n\n          -  Any finding suggestive of peripheral neuropathy found at baseline neurological exam.\n             If a patient has an isolated finding of an absent achilles reflex he may be entered\n             if no signs or symptoms and no other findings are suggestive of peripheral\n             neuropathy.\n\n          -  Concomitant treatment with excluded medications. Excluded medications include any\n             other experimental drugs (including ddI), drugs with known nephrotoxic or hepatotoxic\n             potential, and drugs likely to cause peripheral neuropathy. Any = or > Grade 3\n             laboratory or clinical abnormality or any severe abnormality not listed requires\n             permission from the medical monitor to be entered into this study..\n\n          -  Unwillingness or deemed unable to sign informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002256", 
            "org_study_id": "031D", 
            "secondary_id": "N3663"
        }, 
        "intervention": {
            "intervention_name": "Zalcitabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Zalcitabine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Zalcitabine", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nutley", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "071101199"
                }, 
                "name": "Hoffmann - La Roche Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002256"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1994"
    }, 
    "geocoordinates": {
        "Hoffmann - La Roche Inc": "40.822 -74.16"
    }
}